The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry

Purpose This study determines the prognostic impact of body mass index (BMI) in patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2−) advanced (i.e., metastatic) breast cancer (ABC). Methods All patients with HR+/HER2− ABC who received endocrine therap...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2024-01, Vol.203 (2), p.339-349
Hauptverfasser:	Lammers, Senna W. M., Thurisch, Hannah, Vriens, Ingeborg J. H., Meegdes, Marissa, Engelen, Sanne M. E., Erdkamp, Frans L. G., Dercksen, M. Wouter, Vriens, Birgit E. P. J., Aaldering, Kirsten N. A., Pepels, Manon J. A. E., van de Winkel, Linda M. H., Peters, Natascha A. J. B., Tol, Jolien, Heijns, Joan B., van de Wouw, Agnes J., Teeuwen, Nathalie J. A., Geurts, Sandra M. E., Tjan-Heijnen, Vivianne C. G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Body Mass Index Body weight Breast cancer Breast Neoplasms - complications Breast Neoplasms - epidemiology Breast Neoplasms - metabolism Cancer Cancer research Care and treatment Comparative analysis Cyclin-dependent kinase Cyclin-dependent kinase 4 Cyclin-dependent kinases Development and progression Endocrine therapy Epidemiology Epidermal growth factor ErbB-2 protein Female Fulvestrant Humans Kinases Medicine Medicine & Public Health Metastases Metastasis Obesity Obesity - complications Obesity - epidemiology Oncology Oncology, Experimental Overweight Overweight - complications Overweight - epidemiology Prognosis Survival Thinness - complications Underweight
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose This study determines the prognostic impact of body mass index (BMI) in patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2−) advanced (i.e., metastatic) breast cancer (ABC). Methods All patients with HR+/HER2− ABC who received endocrine therapy +—a cyclin-dependent kinase 4/6 inhibitor as first-given systemic therapy in 2007–2020 in the Netherlands were identified from the Southeast Netherlands Advanced Breast Cancer (SONABRE) registry (NCT03577197). Patients were categorised as underweight (BMI:
ISSN:	0167-6806 1573-7217
DOI:	10.1007/s10549-023-07108-6